Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens.
People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a range of information related to their diabetes. This includes dose timing and the amount of insulin taken, plus how those metrics impact their individual glucose patterns.
The connected pens include the Novo Nordisk NovoPen 6 or NovoPen Echo Plus. When users tap their pen against their smartphone, they automatically upload their insulin dose data to the FreeStyle LibreLink app. It all appears viewable alongside their glucose data, all in one place.
According to a news release, healthcare professionals often ask those with diabetes to keep a record of their insulin dose data. This process can present challenges including missing, incomplete or inaccurate data while also consuming time.
Novo Nordisk aims to make diabetes management decisions easier
“Individually, these two technologies provide valuable information for people managing their diabetes,” said Somerset Foundation Trust nurse consultant Su Down. “Linked together, however, they can provide additional insight into the impact of both dosing and timing of injection on glucose levels. Providing people with diabetes and health care professionals with this insightful information offers an additional perspective, much like adding another piece to the puzzle — we see more of the overall picture, on which to base diabetes management decisions.”
Novo Nordisk said it believes the digital health offering can support patients and providers with reliable information. Its partnership with Abbot represents one step toward bringing the technology to “as many people as possible.”
“People living with diabetes can make up to 180 additional health-related decisions a day compared to people without diabetes. The constant multi-tasking can be emotionally and physically draining,” said Pinder Sahota, GM, Novo Nordisk UK. “I hope that bringing glucose and insulin data together in one place will make some of these decisions a little easier, giving people living with diabetes in the UK more time and energy back for day-to-day life.”